XPR – Lifestyle Demo
Author:
Biovica International
New ESMO Data Highlights TKa Across Multiple Treatment Settings
April 30, 2026
Theis Kipling to Assume Role as CEO of Biovica on May 1, 2026
April 16, 2026
Theis Kipling New CEO for Biovica
April 7, 2026
Biovica International AB – Q3 Interim Report Nov 2025-Jan2026
March 18, 2026
New AACR Data Expand Evidence for TKa In Immunotherapy-Treated Patients and CDK Inhibitor Dose Optimization
March 18, 2026
Nomination Committee for Biovica International AB for the 2026 Annual General Meeting
March 9, 2026